Compare AI & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AI | STOK |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2020 | 2019 |
| Metric | AI | STOK |
|---|---|---|
| Price | $15.09 | $30.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 9 |
| Target Price | $24.29 | ★ $31.00 |
| AVG Volume (30 Days) | ★ 7.1M | 919.7K |
| Earning Date | 12-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.68 |
| Revenue | ★ $352,913,000.00 | $205,632,000.00 |
| Revenue This Year | N/A | $430.24 |
| Revenue Next Year | $11.61 | N/A |
| P/E Ratio | ★ N/A | $45.09 |
| Revenue Growth | 1.84 | ★ 1128.17 |
| 52 Week Low | $12.59 | $5.35 |
| 52 Week High | $45.08 | $38.69 |
| Indicator | AI | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 49.69 | 58.81 |
| Support Level | $13.99 | $28.74 |
| Resistance Level | $15.87 | $31.44 |
| Average True Range (ATR) | 0.75 | 1.83 |
| MACD | 0.30 | 0.30 |
| Stochastic Oscillator | 75.91 | 81.78 |
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.